Medtronic has announced new enhancements to its AccuRhythm AI algorithm technology in Western Europe to improve atrial fibrillation (AF) false alert detection from 74.1% to 88.2% while preserving 99% of true AF alerts. 

AccuRhythm AI is an artificial intelligence algorithm that improves the accuracy of heart rhythm event data from the Medtronic LINQ II insertable cardiac monitor (ICM) so physicians can better care for people with abnormal heart rhythms.

The LINQ family of insertable cardiac monitors (ICMs) provide continuous, long-term monitoring for patients with increased risk of abnormal heart rhythms who experience infrequent symptoms including dizziness, palpitations, syncope (fainting) and chest pain, or who have had a cardioembolic stroke of unknown cause and atrial fibrillation (AF) is suspected as a possible cause. These patients are therefore requiring long-term monitoring or ongoing management.

Medtronic first introduced AccuRhythm AI algorithms in 2022 specific to the most common ICM false alerts, AF and Pause (asystole), which has shown to reduce the number of false alerts by as much as 84%, saving clinicians in Western Europe approximately 160 hours of clinic review time annually (for every 100 LINQ II patients).

AF and Pause generate approximately 90% of false alerts in the ICM space.  The enhancement to the AF algorithm is anticipated to further reduce clinic review time by an additional 40 hours, bringing a total time saving for the clinic to 200 hours annually.

Medtronic developed the AccuRhythm AI platform and algorithms using its database of more than one million electrocardiogram heart rhythm episodes. Medtronic will continue to apply AccuRhythm AI in the cloud automatically to facilitate seamless care for patients.

AccuRhythm AI algorithm technology was recently named the winner of the 7th annual MedTech Breakthrough Awards program as the “Best New Monitoring Solution.”